Blog

Elias Karam: ACCENT pooled analysis published in JCO

Photo of Benoist Chibaudel from ccconcorde.org

Sep 10, 2024, 04:33

Elias Karam: ACCENT pooled analysis published in JCO

Auhtors: Benoist Chibaudel, Morteza Raeisi, Romain Cohen, Greg Yothers, Richard M. Goldberg, Jean-Baptiste Bachet, Norman Wolmark, Takayuki Yoshino, Hans-Joachim Schmoll, Rachel Kerr, Sara Lonardi, Thomas J. George, Einat Shacham-Shmueli, Qian Shi, Thierry André, Aimery de Gramont.

“ACCENT pooled analysis published in JCO:
No benefit of OX was observed for OS in either the low-risk or even in high-risk patient subgroup, stage II colon cancer
OX should not be anymore our standard of care even in high risk stage II colon cancer population.
FP (CAPE or 5-FU) does the job.”

Source: Elias Karam/LinkedIn

Aimery de Gramont Benoist Chibaudel cancer Colon cancer Einat Shacham-Shmueli Elias Karam Greg Yothers Hans-Joachim Schmoll Jean-Baptiste Bachet Journal of Clinic Oncology Morteza Raeisi Norman Wolmark OncoDaily Oncology Qian Shi Rachel Kerr Richard M. Goldberg Romain Cohen Sara Lonardi Takayuki Yoshino Thierry Andre Thomas J. George

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage